Full-year guidance raised on strong demand and backlog
Nordson reported record Q2 results and raised full-year guidance on broad-based strength, particularly in semiconductor and industrial end markets. Management highlighted an 18% organic backlog increase and accelerating order entry, while carefully navigating new tariffs and a pension settlement. Record Q2 sales of $741M, up 8% YoY, with 7% organic growth across all three segments.
Buzzberg readFull-year guidance raised on strong demand and backlogNordson reported record Q2 results and raised full-year guidance on broad-based strength, particularly in semiconductor and industrial end markets. Management highlighted an 18% organic backlog increase and accelerating order entry, while carefully navigating new tariffs and a pension settlement. Record Q2 sales of $741M, up 8% YoY, with 7% organic growth across all three segments.Read full analysisCollapse analysis
Nordson reported record Q2 results and raised full-year guidance on broad-based strength, particularly in semiconductor and industrial end markets. Management highlighted an 18% organic backlog increase and accelerating order entry, while carefully navigating new tariffs and a pension settlement. Record Q2 sales of $741M, up 8% YoY, with 7% organic growth across all three segments.
Raised FY26 revenue guidance to $2.93-3.00B and EPS to $11.30-11.80, citing strong backlog and order momentum.
Backlog up 18% organically YoY, with ATS (semiconductor capital equipment) a significant contributor.
Completed a $13M precision agriculture acquisition (Capstan), paying 9x EBITDA to expand in North American mid-tier OEMs.
Revenue$0.7408B
+11% QoQ
EPS$2.86
+21% QoQ
Gross margin54.54%
reported
Op margin26.62%
reported
What changed this quarter
01
Guidance
Full-year guidance raised on strong demand and backlog
Guidance · revenue to $2.965B
02
Demand
Backlog up 18% organically with broad-based strength
Management highlighted record results, strong backlog growth, and raised guidance, expressing high confidence in the midpoint while noting upside potential.
03
Semiconductors
ATS sees record sales and early-stage semiconductor cycle
Raised FY26 revenue guidance to $2.93-3.00B and EPS to $11.30-11.80, citing strong backlog and order momentum.
04
Medical
Medical returning to normalized growth after slow start
Backlog up 18% organically YoY, with ATS (semiconductor capital equipment) a significant contributor.
Demand
Demand
Bookings & conversion
Backlog up 18% organically with broad-based strength. Management highlighted record results, strong backlog growth, and raised guidance, expressing high confidence in the midpoint while noting upside potential.
Tone · Upbeat
Management highlighted record results, strong backlog growth, and raised guidance, expressing high confidence in the midpoint while noting upside potential.
Supply-chain alpha
A1
The company sees 18% organic backlog growth, with particular strength in the ATS segment, indicating robust demand in semiconductor packaging equipment.
For the first time in quarters, the company noted industrial coatings and polymer processing demand is improving, signaling a broad-based industrial recovery beyond electronics and medical.
The company sees 18% organic backlog growth, with particular strength in the ATS segment, indicating robust demand in semiconductor packaging equipment. — Strong bookings for packaging and test equipment from a diversified supplier suggests ongoing strength and expansion in advanced packaging capacity, which is a key enabler for AI accelerators.
understood thank you for the color and then maybe over to the semiconductor facing business can just kind of review how you're thinking about nordstrom's positioning there in views on cycle durability and maybe a little bit more granularity or quantification to the extent you can on how this cycle is reading through into orders and backlog thank you yeah
The ATS segment, if you look at our 18% backlog growth, is one of the strongest because of robust backlog growth in ATS. And if you remember and recall some of the conversation we had a number of years ago, during the downturn, one of the best things our teams did was to reposition the business in a couple of different areas. We diversified away from just our dispense businesses. Now we have testing inspection businesses that are delivering growth. In addition, we also had a real nice work that was done around diversification of customers going away from Reliance or one or two large customers. And third, we were able to optimally reposition our footprint so that we are in regions where our customers need us to be. So three things of work that we've done in this period of time that has allowed us to position the business. But on top of this, what you have is our close to the customer business model, allowing us to innovate on technologies that are needed for our customers as the new AI applications occur as AI infrastructure happens and semiconductors become more complex, more difficult to manufacture. So all these three things, you know, diversifying customers, operationally being where our customers need us to be, innovating on technologies and applications they need us to be, sort of has allowed us to be in this place that we are benefiting from this robust market growth you know where is where are we at on the cycle i would tell you we're in the early stages it is as always we know this is a difficult business to predict but based on what you can see in the marketplace based on what you can see with our customers i would definitely tell you we're in the early stages um in terms of number of applications If you think about this business, over 50% of this business is in semiconductor now. And so there are numerous applications that we are part of. Lots of new technologies. I think we have talked about with you around where we are headed in this cycle. There is more technology and innovation that is happening in this business that will allow our customers to really get after the AI compute needs that they have. And so a couple of things that you would probably be reading about is panel level packaging. It's very, very early stage, but we are participating in developing these technologies. If you think about optical fibers and increased content of optical …
For the first time in quarters, the company noted industrial coatings and polymer processing demand is improving, signaling a broad-based industrial recovery beyond electronics and medical. — The turn in the industrial segment for precision dispensing suggests a broader manufacturing capex recovery is underway, which also benefits precision agriculture customers.